Chronic treatment with a novel γ‐secretase modulator, JNJ‐40418677, inhibits amyloid plaque formation in a mouse model of Alzheimer's disease

Abstract

JNJ-40418677 selectively decreased Aβ42 production, showed an excellent brain penetration after oral administration in mice and lowered brain Aβ burden in Tg2576 mice after chronic treatment. JNJ-40418677 therefore warrants further investigation as a potentially effective disease-modifying therapy for AD.